2018 Epilepsy Foundation Pipeline Conference

Every two years, the Epilepsy Foundation holds its Pipeline Conference to bring together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation, and product development. This exciting meeting provides a forum for surveying new therapies in development, exploring future advancements, and encouraging collaborations and partnerships.

This year’s Pipeline Conference will take place February 22-23, 2018, at the Westin St. Francis hotel in San Francisco, California. This conference will also feature a Community Day on Saturday, February 24th, where people living with epilepsy and their family, friends, and advocates gather for a day of learning, support, and networking.

Speakers and attendees will include

  • emerging biotech and medical technology companies,
  • major pharmaceutical and device companies, and
  • researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances.

Online registration is now closed.

Registration will be available on site, at the conference.

Draft Conference Agenda

Times are pacific standard time (PST).

Day 1 – Thursday, February 22, 2018

Welcome and Overview – 8:00-8:15 a.m. 

  • Phil Gattone M.Ed, President and CEO, Epilepsy Foundation
  • Jacqueline French MD, Chief Scientific Officer, Epilepsy Foundation
  • Jody Iorns, Executive Director, Epilepsy Foundation Northern California

Session I: Technology in Epilepsy: Changing Trials and Therapeutics – 8:15-9:20 a.m. 

Moderator: Daniel Friedman MD, Associate Professor, Department of Neurology, NYU Langone Medical Center

  • Seizure Diary – John Hixson MD, Associate Professor, University of California-San Diego
  • Seizure Prediction/Gauge – Gregory Worrell MD, PhD, Professor of Neurology, Mayo Clinic, Rochestor, Minnesota
  • Seizure Detection Device – Robert Fisher MD, PhD, Maslah Saul Professor, Department of Neurology, Standford University Medical Center
  • Panel Discussion

Session II: Pre-Clinical Drugs – 9:20-10:40 a.m.

Moderator: Karen Wilcox PhD, Professor and Chair, University of Utah, College of Pharmacy

  • Propofol – Michael Rogawski MD, PhD, EpaleX
  • 2DG – Thomas Sutula MD, PhD, NeuroGenomeX, Inc.
  • TAK935/OV935 – Mahnaz Asgharnejad PharmD, Ovid/Takeda
  • Adenosine-Augmentation Therapies – Deltev Boison PhD, R.S. Dow Neurobiological Laboratoires and Legacy Research Institute
  • Pre-clinical Padsevonil – Rafal Kaminski MD, PhD, Senior Director and Head of Epilepsy, UCB Pharma
  • Injectable Diazepam: XeriJect – Steven Prestrelski PhD, Xeris
  • Novel mTOR Inhibitors – Wolfgang Löscher PhD, Professor and Head of the Department of Pharmacology, University of Veterinary Medicine Hannover, and Head of the Center for Systems Neuroscience, Hannover, Germany
  • SAGE-324 – Rebecca Hammond PhD, Director, In Vivo Pharmacology, Sage Therapeutics 

Networking Break: Poster Presentations – 10:40-11:00 a.m.

  • SUDEP Biomarker Challenge: Early Detection of Myacardial Injury as a Biomarker for SUDEP in Living Epilepsy Patients – Barbara L. Kroner PhD, John M. Schreiber MD, Lowell H. Frank MD

Session III: Epilepsy development – Regulatory and financing considerations: How to get your investment and how to get your investment to pay off – 11:10 a.m.-12:25 p.m. 

Moderator: Karen Bergman, Vice President, Investor Relations and Corporate Communications, FibroGen, Inc.

  • Talk 1: Will epilepsy drugs be able to be reimbursed without comparative data showing superiority, and if you need comparative data, how do you get it?
    • How to make a difference: The role of comparative data in AED development: Konrad Werhahn MD, Senior Medical Director, Global Clinical Development, UCB Pharma
    • Payer Perspective
    • If comparative superiority data is needed, how is it acquired?: Daniel Friedman MD, Associate Professor, Department of Neurology, NYU
    • Preclinical Differentation Efforts in the NINDS Epilepsy Therapy Screening Program: John Kehne PhD, Program Director, ETSP/NINDS
  • Panel Discussion
  • Talk 2: Orphan versus broad market development
    • Dr. Jeremy Levin BChir, MB, DPhil, Chairman of the Board of Directors and CEO, Ovid Therapeutics
    • Liza Squires MD, Chief Medical Officer, Zynerba Pharmaceuticals
  • Panel Discussion

Networking Lunch – 12:25-1:30 p.m.

Session IV: Early Stage Devices – 1:35 p.m.-1:55 p.m.

Moderator: Kimford Meador MD, Professor, Department of Neurology and Neurological Sciences, Stanford University School of Medicine

  • Epilog PreOp Ictal – Gregor Strobbe, CEO, Epilog
  • IMI CNS RADAR – Mark Richardson PhD, Innovative Medicines Initiative, Professor, King's College London

Session V: Regulatory Requirements for Seizures/Epilepsy Devices (e.g., What would be the regulatory requirements for an implanted device?) – 1:55-2:35 p.m. 

  • Speaker: William Heetderks MD, PhD, Clinical Deputy, Division of Neurological and Physical Medicine Devices, Office of Device Evaluation, Food and Drug Administration
  • Q & A

Networking Break: Poster Presentations – 2:35-3:00 p.m.

  • SUDEP Biomarker Challenge: Cardio-Respiratory Biomarkers of SUDEP from an Unobtrusive Wearable Monitor – Kristen H. Gilchrist PhD, Meghan Hegarty-Craver PhD, William Gaillard MD

Update from 2017 Shark Tank Winners – 3:05-3:30 p.m.

  • Introduction by Jacqueline French MD, Chief Scientific Officer, Epilepsy Foundation
  • Jonas Duun-Henriksen PhD, Senior Scientific Researcher at UNEEG medical A/S: 24/7 EEG SubQ in the wild won $75,000 in the audience vote for the People’s Choice Award.
  • Paula Gomez PhD, CEO of Epistemic, and Hilda A. Cerdeira PhD, Fellow of the America Physical Society: "Epistemic: Device for epileptic seizure prediction" won $50,000 awarded by the judges.

Shark Tank Competition – 3:30-5:10 p.m.

Co-Moderators: Jacqueline French MD, Chief Scientific Officer, Epilepsy Foundation, and John O'Hurley, Actor, Philanthropist

  • Sharks:
    • Tony Coelho
    • Robert Fisher MD, PhD, Professor, Department of Neurology, Stanford University Medical Center
    • Daniel Friedman MD, Associate Professor, Department of Neurology, NYU Langone Medical Center
    • Elizabeth Garofalo MD, Principal, EAG Pharma Consulting
    • Shivkumar Sabesan PhD, Staff Hardware Engineer, Verily Life Sciences LLC
  • Finalists:
    • Automated detection of epileptic lesions from MRI
    • Machine vision based solution for noninvasive seizure quantification and alarm
    • Repositioning compounds for use in refractory epilepsy
    • Improved surgical outcomes with 3D scanning
    • Korwave
    • Virtual reality simulations for the management of status epilepticus

Accelerator Award Reception & Award Presentation – 6:00-8:00 p.m.

Day 2 – Friday, February 23, 2018

Session VI: Social Innovation and Power of Partnerships – 8:05-8:55 a.m.

Moderator: Brandy Fureman PhD, Vice President of Research and New Therapies, Epilepsy Foundation

  • The Epilepsy Foundation – Brandy Fureman PhD, Vice President of Research and New Therapies, Epilepsy Foundation
  • The Epilepsy Study Consortium – Jacqueline French MD
  • Citizens United for Research in Epilepsy (CURE): Infantile Spasms Initiative – Laura Lubbers PhD, Chief Scientific Officer, CURE
  • Tuberous Sclerosis Alliance: Preclinical Trial Consortium – Steve Roberds PhD, Chief Scientific Officer, Tuberous Sclerosis Alliance
  • Pediatric Epilepsy Research Foundation (PERC) & Pediatric Epilepsy Research Consortium – Kelly Knupp MD, Children’s Hospital Colorado
  • Panel Discussion

Session VII: The Value of Registries – 8:55-9:45 a.m. 

Moderator: Deborah Hirtz MD, Professor, Neurological Sciences and Pediatrics, University of Vermont School of Medicine

  • Human Epilepsy Project (HEP & HEP 2) – Daniel Lowenstein MD, Executive Vice Chancellor and Provost, University of California-San Diego
  • Rare Epilepsy Network (REN) – Dale Hesdorffer PhD, Professor of Epidemilogy at the Columbia University Medical Center
  • Registry Participant Perspective – Ms. Monica Weldon, President and CEO, Bridge the Gap SYNGAP, and mother of a child with a rare epilepsy
  • Panel Discussion / Q & A

Networking Break: Poster Presentations – 9:45-10:10 a.m.

  • SUDEP Biomarker Challenge: Multivariate computer based classification of biomarkers for SUDEP – Peter Carlen MD, Berj Bardakjian PhD, Stiliyan Kalitzin PhD, and Martin del Campo MD. 

Session VIII: Clinical Devices – 10:20-11:40 a.m.

Moderator: Josef Parvizi MD, PhD, Professor, Department of Neurology, Standford University Medical Center

  • StarStim – Ana Maiques, CEO, Neuroelectrics
  • Embrace Seizure Detection Watch – Matteo Lai, Co-Founder and CEO, Empatica
  • Epilog, Wearable Seizure Diary – Mitchell Frankel PhD, Signal Processing Engineer, Epitel
  • SPEAC System – Luke Whitmire PhD, Chief Science Officer, Brain Sentinel, Inc.
  • Intraventricular valproate – Daniel Abrams MD, Cerebral Therapeutics
  • Cardioprotective Effects of Vagus Nerve Stimulation (VNS Therapy®) in Epilepsy – Richard Verrier PhD, LivaNova
  • Neuronaute – Dr. Samir Medjebar, Business Development Director, Bioserenity
  • Wireless, dry electrode, medical grade EEG headset – Aswin Gunasekar MS, MBA, Founder, Zeto Inc.

Session IX: The Research Roundtable for Epilepsy – 11:40 a.m.-12:15 p.m.

  • Introduction to the Research Roundtable for Epilepsy Initiative – Brandy Fureman PhD, Vice President, Research and New Therapies, Epilepsy Foundation
  • 2016 Meeting Goals and Deliverables – Jacqueline French MD, Chief Scientific Officer, Epilepsy Foundation
  • 2017 Meeting Goals and Deliverables – Kelly Knupp MD, Associate Professor of Pediatrics and Neurology, Department of Neurology and Neurodiagnostics, Children's Hospital Colorado
  • 2018 Meeting Goals and Deliverables – Brandy Fureman PhD, Vice President, Research and New Therapies, Epilepsy Foundation
  • Panel Discussion

Networking Lunch – 12:25-1:25 p.m.

Session X: Clinical Drugs 1 – 1:30-2:30 p.m.

Moderator: Pavel Klein MD, Director, Mid-Atlantic Epilepsy and Sleep Center

  • BIS-001 ER – Stephen D. Collins MD, PhD, Biscayne/Insero
  • ZYN002, CBD Gel – Donna Gutterman PharmD, Zynerba
  • ZX008, Low-Dose Fenfluramine – Glen Morrison PhD, Zogenix
  • Staccato Alprazolam – Jouko Isojarvi MD, PhD, Engage Therapeutics Inc.
  • XEN1101 – Y. Paul Goldberg MBChB, PhD, FRCPC, Xenon
  • Ganaxolone – Julia Tsai PhD, Executive Director, Clinical Development, Marinus
  • NRL-1, Intranasal Diazepam – Craig Chambliss, President & CEO, Neurelis

Networking Break: Poster Presentations – 2:30-2:50 p.m.

  • SUDEP Biomarker Challenge: PRESUDE - Brainstem MRI biomarker to Predict the risk of Sudden Unexpected Death in Epilepsy – Carolina Ciumas PhD, Philippe Ryvlin MD, PhD, Samden Lhatoo MD

Session X: Clinical Drugs 2 – 2:50-4:00 p.m.

Moderator: Pavel Klein MD, Director, Mid-Atlantic Epilepsy and Sleep Center

  • Clinical Padsevonil – Pierandrea Muglia MD, Vice President & Head Neuroscience Discovery Medicine, UCB Pharma
  • PF-06372865 – Rachel Gurrell, Clinical Lead, Early Clinical Development, Pfizer
  • TIL-TC150 – Dr. Bláthnaid McCoy MB BCh, BAO, MRCPI, CSCSN (EEG), MSc, Program Director, Neurology Residency & Epilepsy Fellowship Programs; Assistant Professor of Pediatrics, University of Toronto; Pediatric Neurologist, Hospital for Sick Children Toronto, Tillray
  • CX-8998 and CX-5395 – Spyros Papapetropoulos MD, PhD, Head of Research and Development and Chief Medical Officer at Cavion, Inc. 
  • Epidiolex (cannabidiol, CBD) in rare epilepsy syndromes and the GW/Greenwich Biosciences pipeline – Volker Knappertz MD, GW/Greenwich Biosciences
  • Clobazam Oral Soluble Film and Diazepam Buccal Soluble Film – Michael Rogawski MD, PhD, Medical Advisor, MonoSol Rx, Professor of Neurology and Pharmacology, University of California Davis

Closing Remarks – 4:00-4:05 p.m.

Final Networking Reception – 4:05-5:05 p.m.

Thank You to Our Sponsors 

Zogenix_logo_with green swoosh_RGB_7 inches wide at 300ppi.jpg
 
UCB
 
SupernusFinal4C_MAIN (R).jpg
 

Additional Sponsors Include:

  • Axcella Health
  • Danny Did Foundation
  • LivaNova
  • Lundbeck
  • Medtronic
  • Sage Therapeutics
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Zynerba Pharmaceuticals